|

PORT-77 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2/3: 1

Top Sponsors

  • Portal Therapeutics, Inc.1

Indications

  • EPP21
  • X-Linked Protoporphyria (XLP)1
  • Erythropoietic Protoporphyria (EPP)1
  • Liver Disease1

Huntington Beach, California1 trial

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

Investigative Site

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.